The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vonoprazan: First Global Approval

(2015) Karly P. Garnock-Jones   DRUGS

Mo1147 A Crossover Study to Evaluate the Acid-Inhibitory Effect of a Newly Developed Potassium-Competitive Acid Blocker, Vonoprazan, Compared With Esomeprazole or Rabeprazole

(2015) Yuuichi Sakurai et al.   GASTROENTEROLOGY

412 A Phase 3, Lansoprazole-Controlled, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vonoprazan (10 mg or 20 mg) for Prevention of Recurrent Peptic Ulcers During Long-Term Therapy With Non-Steroidal Anti-Inflammatory Drug (NSAID)

(2015) Yuji Mizokami et al.   GASTROENTEROLOGY

Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis

(2014) Eiji Umegaki et al.   GASTROENTEROLOGY

Tu1055 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Low-Dose Aspirin Therapy: Results of a Phase 3 Trial

(2014) Takashi Kawai et al.   GASTROENTEROLOGY

Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

(2014) Kazunari Murakami et al.   GASTROENTEROLOGY

Tu1054 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy: Results of a Phase 3 Trial

(2014) Yuji Mizokami et al.   GASTROENTEROLOGY

Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis

(2014) Katsuhiko Iwakiri et al.   GASTROENTEROLOGY

Helicobacter pyloriand Public Health

(2014) Anthony Axon   HELICOBACTER

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Individualized Therapy for Gastroesophageal Reflux Disease

(2012) Takahisa Furuta et al.   Molecular Diagnosis & Therapy

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

Drug-Drug Interaction Profiles of Proton Pump Inhibitors

(2010) Ryuichi Ogawa et al.   CLINICAL PHARMACOKINETICS

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Proton Pump Inhibitors

(2009) Kwong Ming Fock et al.   CLINICAL PHARMACOKINETICS